Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with concurrent radiotherapy for esophageal cancer
ChiCTR2000039176Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in esophageal cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: overall survival. Started Nov 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2000039176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039176.